EMMANUELLE LAURENCE WAUBANT

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis
    Emmanuelle Waubant
    Regional Pediatric Multiple Sclerosis Center, University of California San Francisco, San Francisco, CA 94158, USA
    Mult Scler 19:891-5. 2013
  2. pmc Common viruses associated with lower pediatric multiple sclerosis risk
    E Waubant
    UCSF Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
    Neurology 76:1989-95. 2011
  3. doi Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults
    Emmanuelle Waubant
    UCSF Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Ave, Ste 908, San Francisco, CA 94117, USA
    Arch Neurol 66:967-71. 2009
  4. ncbi Pediatric multiple sclerosis
    Emmanuelle Waubant
    Emmanuelle Waubant, MD, PhD University of California San Francisco, Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Curr Treat Options Neurol 11:203-10. 2009
  5. ncbi Spotlight on anti-CD20
    E Waubant
    UCSF MS Center, 350 Parnassus Street, Suite 908, San Francisco, California 94117, USA
    Int MS J 15:19-25. 2008
  6. ncbi Emerging therapies for MS
    E Waubant
    UCSF MS Center, University of California San Francisco, 350 Parnassus Street, San Francisco, CA 94117, USA
    Rev Neurol (Paris) 163:688-96. 2007
  7. doi Predictors of the location of multiple sclerosis relapse
    S Deen
    Multiple Sclerosis Center, University of California at San Francisco, San Francisco, California 94117, USA
    J Neurol Neurosurg Psychiatry 79:1190-3. 2008
  8. ncbi Are initial demyelinating event recovery and time to second event under differential control?
    T West
    University of California San Francisco Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Neurology 67:809-13. 2006
  9. pmc Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures
    E M Mowry
    Department of Neurology, University of California, San Francisco, 94117, USA
    Neurology 72:1760-5. 2009
  10. pmc Demyelinating events in early multiple sclerosis have inherent severity and recovery
    E M Mowry
    Department of Neurology, Multiple Sclerosis Center, University of California, San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Neurology 72:602-8. 2009

Research Grants

  1. Environmental and genetic risk factors for pediatric MS
    EMMANUELLE LAURENCE WAUBANT; Fiscal Year: 2010

Detail Information

Publications26

  1. pmc Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis
    Emmanuelle Waubant
    Regional Pediatric Multiple Sclerosis Center, University of California San Francisco, San Francisco, CA 94158, USA
    Mult Scler 19:891-5. 2013
    ..Our aim was to determine if MS patients who were positive for these viruses had higher levels of antibodies to these viruses. We also assessed whether human leukocyte antigen (HLA)-DRB1*1501 genotype influenced viral antibody levels...
  2. pmc Common viruses associated with lower pediatric multiple sclerosis risk
    E Waubant
    UCSF Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
    Neurology 76:1989-95. 2011
    ..We studied seroprevalence for Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) type 1 and HLA-DRB1*1501/1503 status as predictors of pediatric MS...
  3. doi Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults
    Emmanuelle Waubant
    UCSF Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Ave, Ste 908, San Francisco, CA 94117, USA
    Arch Neurol 66:967-71. 2009
    ..To compare initial brain magnetic resonance imaging (MRI) characteristics of children and adults at multiple sclerosis (MS) onset...
  4. ncbi Pediatric multiple sclerosis
    Emmanuelle Waubant
    Emmanuelle Waubant, MD, PhD University of California San Francisco, Regional Pediatric Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Curr Treat Options Neurol 11:203-10. 2009
    ..Recent data suggest that some children experience a disease breakthrough on first-line therapies approved for adult MS, and thus second-line therapies must be considered...
  5. ncbi Spotlight on anti-CD20
    E Waubant
    UCSF MS Center, 350 Parnassus Street, Suite 908, San Francisco, California 94117, USA
    Int MS J 15:19-25. 2008
    ..This review will present the rational for B-cell based therapies in MS and related diseases and preliminary data suggesting a therapeutic benefit in MS and related diseases. In addition, other therapies aiming at CD20 will be reviewed...
  6. ncbi Emerging therapies for MS
    E Waubant
    UCSF MS Center, University of California San Francisco, 350 Parnassus Street, San Francisco, CA 94117, USA
    Rev Neurol (Paris) 163:688-96. 2007
    ..Finally, new therapeutic approaches are now also addressing neuroprotection and CNS repair...
  7. doi Predictors of the location of multiple sclerosis relapse
    S Deen
    Multiple Sclerosis Center, University of California at San Francisco, San Francisco, California 94117, USA
    J Neurol Neurosurg Psychiatry 79:1190-3. 2008
    ..This study sought to identify predictors of MS relapse location. Based on the current literature, two potential predictors were identified: treatment with interferon beta (IFNB) and location of previous relapse...
  8. ncbi Are initial demyelinating event recovery and time to second event under differential control?
    T West
    University of California San Francisco Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Neurology 67:809-13. 2006
    ..The authors speculate that IDE recovery and time to second event are under separate biologic or genetic control, and as such, their clinical predictors are different...
  9. pmc Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures
    E M Mowry
    Department of Neurology, University of California, San Francisco, 94117, USA
    Neurology 72:1760-5. 2009
    ..Health-related quality of life (HRQOL) is reduced in multiple sclerosis (MS). It is unclear whether HRQOL is associated with white matter lesion burden or measures of brain atrophy...
  10. pmc Demyelinating events in early multiple sclerosis have inherent severity and recovery
    E M Mowry
    Department of Neurology, Multiple Sclerosis Center, University of California, San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA
    Neurology 72:602-8. 2009
    ..We sought to identify the factors associated with relapse severity and recovery and to evaluate whether events have inherent severity or recovery...
  11. doi Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome
    D T Okuda
    Department of Neurology, University of California San Francisco, UCSF Multiple Sclerosis Center, San Francisco, CA 94117, USA
    Neurology 72:800-5. 2009
    ..Routinely encountered in clinical practice, the natural history or evolution of such individuals with respect to their risk of developing multiple sclerosis (MS) is unclear...
  12. doi The onset location of multiple sclerosis predicts the location of subsequent relapses
    E M Mowry
    Department of Neurology, University of California, Multiple Sclerosis Center, San Francisco, CA 94117, USA
    J Neurol Neurosurg Psychiatry 80:400-3. 2009
    ..We sought to determine if initial clinical demyelinating event (IDE) location predicts subsequent clinical relapse locations in early RRMS...
  13. doi Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?
    D Chabas
    UCSF Regional Pediatric Multiple Sclerosis Center, San Francisco, CA 94117, USA
    Neurology 71:1090-3. 2008
    ..Pediatric patients with MS may less often meet MRI diagnostic criteria for adults. Whether initial MRI presentation is distinct in prepubertal patients is unknown...
  14. ncbi IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS
    E Waubant
    UCSF Multiple Sclerosis Center, University of California, San Francisco 94117, USA
    Neurology 60:52-7. 2003
    ....
  15. ncbi Clinical characteristics of responders to interferon therapy for relapsing MS
    E Waubant
    UCSF MS Center, San Francisco, CA 94117, USA
    Neurology 61:184-9. 2003
    ..To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders...
  16. ncbi An open label study of the effects of rituximab in neuromyelitis optica
    B A C Cree
    Multiple Sclerosis Center, University of California, San Francisco 94117, USA
    Neurology 64:1270-2. 2005
    ..Seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up. The pretreatment median Expanded Disability Status Scale score was 7.5, and at follow-up examination was 5.5 (p = 0.013)...
  17. pmc Younger children with MS have a distinct CSF inflammatory profile at disease onset
    D Chabas
    UCSF Regional Pediatric MS Center, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
    Neurology 74:399-405. 2010
    ..The clinical and MRI presentation differs between earlier- and later-onset pediatric multiple sclerosis (MS), whereas the effect of age on the CSF inflammatory profile is unknown and may contribute to delayed diagnosis...
  18. doi Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis
    A Gajofatto
    Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, California, USA
    Mult Scler 15:50-8. 2009
    ..Options for non-responders to relapsing-remitting multiple sclerosis (RRMS) first-line disease-modifying therapies (DMT) are limited. We explored whether switching first-line DMT is effective...
  19. ncbi IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis
    E Waubant
    UCSF Mt Zion Multiple Sclerosis Center, San Francisco, CA 94115, USA
    J Interferon Cytokine Res 21:181-5. 2001
    ..10, p = 0.047; Wilcoxon signed-rank test). These preliminary data suggest that IFN-beta1a therapy may increase TIMP-1 levels...
  20. pmc Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures
    D T Okuda
    UCSF Multiple Sclerosis Center, University of California, San Francisco, San Francisco, California 94117, USA
    Brain 132:250-9. 2009
    ....
  21. ncbi Interferon beta-1a in children with multiple sclerosis is well tolerated
    E Waubant
    UCSF Mt Zion Multiple Sclerosis Center, San Francisco, CA, USA
    Neuropediatrics 32:211-3. 2001
    ..Multiple sclerosis is a chronic demyelinating disease rare in children. Currently marketed disease modifying therapies are limited to adults...
  22. ncbi Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS
    E Waubant
    UCSF Mt Zion Multiple Sclerosis Center, 1701 Divisadero Street, San Francisco, CA 94115, USA
    J Neuroimmunol 112:139-45. 2001
    ....
  23. doi Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
    J A Cohen
    Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 14:370-82. 2008
    ....
  24. ncbi Treatment of pediatric multiple sclerosis and variants
    D Pohl
    Department of Pediatrics and Pediatric Neurology, Georg August University Goettingen, Germany
    Neurology 68:S54-65. 2007
    ..Finally, an overview of symptomatic MS therapies and experiences with these treatments in pediatric patients is provided...
  25. ncbi Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS
    D Brassat
    Department of Neurology, Hopital Purpan, Toulouse University Medical Center, Toulouse, France
    Neurology 59:954-5. 2002
    ..Nevertheless, this case stresses the need to further evaluate the long-term risk of TRAL in patients with MS who receive mitoxantrone...
  26. ncbi Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study
    B Stankoff
    Federation de Neurologie, Hopital de la Salpetriere, AP HP, Paris, France
    Neurology 64:1139-43. 2005
    ..To assess whether modafinil, a wakefulness-promoting agent, is useful for fatigue in patients with multiple sclerosis (MS)...

Research Grants1

  1. Environmental and genetic risk factors for pediatric MS
    EMMANUELLE LAURENCE WAUBANT; Fiscal Year: 2010
    ..The purpose of this study is to investigate potentially important risk factors for MS in children. ..